-
Interested candidates can ping me
#Walkin @ Hetero Biopharma#Biosimilars#Fresherspic.twitter.com/gj0BAwdEJ2
-
Guideline on adjustment for baseline covariates in clinical trials | Reason for using stratified designs - https://ecs.page.link/ndwtZ
#Regulatory#Pharma#MedicalDevice#Biotech#FDA#Health#LifeSciences#ClinicalTrails#Biosimilars#Clinicallife#Biostatisticspic.twitter.com/5fi2v7Ic3z
-
.
@breastoncdoc of@UPMCHillmanCC discusses the emergence of#biosimilars in oncology and how he anticipates they will change the paradigm http://ow.ly/CY0l50yeL2m -
BREAKING:
@Merck announces#biosimilars spin-off company + new HQ in New Jersey near parent campus. 75% of new co.’s sales expected to come from outside U.S. & involve 10k-11k employees under direction of new spin-off CEO Kevin Ali, a 30-yr. Merck veteran. pic.twitter.com/bgoEQiStUL
-
How much does your state save? In 2018, generic prescription medicines saved
#Indiana $6.4B, and $293B for the U.S. health care system overall. Use this interactive map to see how much your state saved: https://rxsavingsmap.org/#GRxBiosimsSavingsReport#generics#biosimilars pic.twitter.com/byuXQ0LXww
-
check out my latest post on
$MCK spin out of hodge-podge product lines including#biosimilars licensed from Samsung Bioepis. Would make sense for$MRK to do another spinout of#biosimilars then do a M&E with$CHRS with better marketing org. Eliminate duplicate R&D. -
$MCK -- new hodge-podge spin out includes#biosimilars marketing org for drugs licensed from Samsung Bioepis. Would make sense for further spin out of pure#biosimilars co and buy$CHRS with better marketing org. Eliminate duplicate R&D (even I can make a bull case for$CHRS) -
#Biosimilars are much much harder to manufacturing than small molecule generics. Tossing off an FDA identified issue with$CHRS newbie European partner’s contract manufacturer process, however small, as “growing pains” ignores fact that patients’ lives are at stake here. -
Looking for information about
#biologics and#biosimilars? Take a peek at our#fact sheet, and learn why we advocate for patient-doctor choice

.
http://bit.ly/2txTY23 pic.twitter.com/KJuz0tenoU
-
Alternate title:
#Biosimilars: Let's not f*** this up https://twitter.com/StanMehr/status/1225067420349620224 …pic.twitter.com/pFHaK4k1nl
-
Do you ever wonder where the US
#biosimilars market is heading, and when it might get there? I've just finished a report that answers this exact question! For drug makers, payers, prescribers, policymakers, and anyone involved in the#biosimilar industry.https://bit.ly/2SihQzq -
Go Behind the Scenes at Teva’s state-of-the-art
#biopharmaceutical facility in Ulm, Germany, and meet the experts who are advancing more treatment options for patients#biopharma#biosimilars http://bit.ly/373iqX4 pic.twitter.com/KyGVdfkz9C
-
Merck to Focus on Key Growth Pillars Through Spinoff of Women’s Health, Trusted Legacy Brands and
#Biosimilars into New Company (“NewCo”) https://www.mrknewsroom.com/news-release/corporate-news/merck-focus-key-growth-pillars-through-spinoff-womens-health-trusted-leg … -
Having an intention to prove yourself to the world? Let's
#Meetup Euro Biosimilars 2020 learn and Explore#GrabThisSplendidOpportunity.#InvestinginOurselves for#BettermentofOurselves.#Hustle#HardWork#universities#students YoungResearcher#Berlin#Germany#Biosimilars #2020 pic.twitter.com/LafUwoYI51
-
China’s Biosimilars Commercialized at an Impressive Speed. A comparison of the biosimilar accessibility in China, the EU, and the U.S. https://www.en-cphi.cn/news/show-59065.html …
#Biosimilars pic.twitter.com/TDvAHXplMp
-
FDA and FTC Say They Will Work Collaboratively to Deter Anticompetitive Behavior: Actions Speak Louder Than Words https://wp.me/p7gt6c-4Yh
#biosimilars -
.
@US_FDA and@FTC talk tough on ensuring competition for biologics https://www.thepharmaletter.com/article/fda-and-ftc-talk-tough-on-ensuring-competition-for-biologics …#biosimilars -
IMHO, your paper is the most important paper on
#biosimilars in 2019. It is THE counter to@peterbachmd argument for heavy regulation (vs#biolosimilar competition) of a biologic therapeutic class once the reference drug loses it patents. -
You state that
#biosimilars are list priced 15% to 35% less than reference drug...implying that#biosimilars are cheaper than reference drugs. You should do more work on getting comparisons of net prices after rebates in the commercial market and report on that -
With the sales growth seen so far and the likely addition of a Remicade biosimilar, Bernstein analyst Ronny Gal said "it's tough to see " Amgen 2020 biosimilar sales of less than $1.8 billion, up from $570 million in 2019.
#biosimilars https://www.biopharmadive.com/news/amgen-pfizer-biosimilar-growth-herceptin-avastin/571502/ …
Čini se da učitavanje traje već neko vrijeme.
Twitter je možda preopterećen ili ima kratkotrajnih poteškoća u radu. Pokušajte ponovno ili potražite dodatne informacije u odjeljku Status Twittera.